A unique class of small molecule BCL-2 inhibitors/BH3-mimetics [5] that specifically block anti-apoptotic BCL-2 proteins has been developed and the BCL-2 specific ABT-199/Venetoclax showed efficacy in the treatment of chronic lymphocytic leukemia [6, 7]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.